|
業務類別
|
Biotechnology |
|
業務概覽
|
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulationof a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR. |
| 公司地址
| 100 Marine Parkway, Suite 400, Redwood City, CA, USA, 94065 |
| 電話號碼
| +1 650 213-8444 |
| 傳真號碼
| +1 650 213-8383 |
| 公司網頁
| https://www.soleno.life |
| 員工數量
| 182 |
| Dr. Michael Huang, M.D. |
Senior Vice President, Clinical Development |
-- |
22/04/2025 |
| Ms. Patricia C. Hirano |
Senior Vice President, Regulatory Affairs |
美元 375.00K |
22/04/2025 |
| Ms. Meredith S. Manning |
Chief Commercial Officer |
美元 415.18K |
22/04/2025 |
| Ms. Jennifer Fulk |
Chief Financial Officer |
-- |
26/02/2026 |
| Ms. Kristen Yen |
Senior Vice President, Global Clinical Operations and Patient Advocacy |
-- |
22/04/2025 |
| Dr. Anish Bhatnagar, M.D. |
President, Chief Executive Officer and Chairman of the Board |
美元 640.00K |
26/02/2026 |
|
|
| Mr. Matthew Pauls, J.D.,M.B.A. |
Lead Independent Director |
25/02/2026 |
| Dr. Birgitte Volck, M.D.,PhD |
Independent Director |
25/02/2026 |
| Dr. Andrew Sinclair, PhD |
Independent Director |
25/02/2026 |
| Dr. Anish Bhatnagar, M.D. |
President, Chief Executive Officer and Chairman of the Board |
26/02/2026 |
| Mr. Mark W. Hahn |
Independent Director |
25/02/2026 |
| Mr. William G. Harris |
Independent Director |
22/04/2025 |
| Ms. Dawn Carter Bir |
Director |
25/02/2026 |
|
|
|
|
